Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | FMT to treat intestinal dysbiosis in GvHD

Florent Malard • 5 Apr 2019
EBMT 2019
General Leukemia
ODYSSEE

Alterations in the gut microbial composition is common during hematopoietic stem cell transplantation (HSCT), and is associated with the development of graft-versus-host disease (GvHD). Florent Malard, MD, PhD, from Hôpital Saint-Antoine, Paris, France, discusses the promises of the Phase II ODYSEE trial (NCT02928523) investigating the use of autologous fecal microbiota transplantation (AFMT) in gut-predominant steroid refractory GvHD patients. Speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany, Dr Malard stresses how using fecal microbiota from a pool of donors can result in high bacterial diversity and successful intestinal recolonization in patients.

More from Florent Malard

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
1:44
PHOEBUS trial: oral fecal microbiotherapy for increasing OS in patients undergoing alloSCT
Florent Malard • 11 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:04
Retrospective study on the outcomes of patients with myeloma treated with cilta-cel and ide-cel
Florent Malard • 20 May 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals